29Nov
28Nov
Hoping to see again, local woman seeks funds for $15,000 device
Three months ago, Donna Witcher, who is legally blind, walked outside her Torresdale home and identified a stop sign. "It was amazing," said Witcher, a buoyant 52-year-old. "I could actually see." The secret to her sudden vision? A high-tech headset called eSight, which employs a tiny camera that sends high-resolution video through a computer and back to small LED screens in front of the viewer's eyes. Read more >>
26Nov
The Carbonite Inc. (CARB) Upgrade by Oppenheimer Holdings Inc. to “Outperform”
Carbonite Inc. (NASDAQ:CARB) was upgraded by investment analysts at Oppenheimer Holdings Inc. from a “market perform” rating to an “outperform” rating in a research note issued on Tuesday. Read more >>
25Nov
Skyline Receives Canada Approval For STREAMWAY System
Going back to the biotech angle, Skyline Medical Inc. (NASDAQ: SKLN) announced that it received approval for its STREAMWAY System and related disposables from Canadian authorities. The company said that a number of distributors had expressed interest in selling STREAMWAY into Canada’s health-care system. Read more >>
24Nov
Carbonite Inc. (CARB) Breaks into New 52-Week High on November 23 Session
Shares of Carbonite Inc. (CARB) broke into a new 52-week high yesterday, hitting a peak of $19.63. Shares closed at $19.55 after opening at $19.45 for a move of 0.77%. The company now has a market cap of $532.9 million. Read more >>
24Nov
Community raises $15K to help legally blind Independence boy see
Thanks to the community, a young boy is going to be able to see better than ever. Corbin Wolfe’s family raised the $15,000 they needed for his eSight eyewear. They’ve ordered it, and it’s on its way. All of Kansas City fell in love with 7-year-old after they saw a video of him trying on eSight for the very first time. It’s new technology using a camera and monitor to help people who are legally blind see. Read more >>
23Nov
Two Biotech Stocks Are Just So Hot Right Now (Corbus Pharmaceuticals Holdings, Inc.)
On November 14, 2016 Corbus Pharmaceuticals Holdings, Inc. (CRBP) announced positive topline results from its Phase 2 study evaluating Resunab (“JBT-101”) for the treatment of diffuse cutaneous systemic sclerosis (“systemic sclerosis”). JBT-101 out-performed placebo in the American College of Rheumatology (ACR) Combined Response Index in diffuse cutaneous Systemic Sclerosis (CRISS) score, reaching 33% at week 16, versus 0% for placebo. Read more >>
23Nov
Skyline Medical (SKLN) Reports Approval in Canada to Market STREAMWAY System
Skyline Medical Inc. (NASDAQ: SKLN) announces that it has received a Medical Device Establishment License to sell the STREAMWAY System and related disposables in Canada. Read more >>
23Nov
Myomo Wants to Help Brain Injury Survivors Overcome Paralysis
For those who experience a stroke or traumatic brain injury, some are left with having to cope and adapt to having a paralyzed or weak limb. According to Cleveland Clinic, patients who have a left-brain stroke may experience paralysis on the right side of their body. Also, as stated by the National Stroke Association, as many as 9 out of 10 stroke survivors have some degree of paralysis immediately following a stroke. Myomo, a medtech company, is working to empower...
22Nov